Hanmi Science Co., Ltd. is a high-risk South Korean pharmaceutical company with a ESG score of 32.5. The company, as a holding company, oversees the manufacturing and distribution of a wide range of pharmaceutical products. These include prescription drugs for various ailments such as neuropathic pain, obesity, epilepsy, oral care, hair growth, and many more. Hanmi Science Co., Ltd. is committed to environmental sustainability and good governance practices in the pharmaceutical industry.